insights_auto
Why is HELP down २.३९%?
Dive Deeperchevron_right
HELP:NASDAQ
Cybin Inc
US$ ११.४२
arrow_downward
-२.३९%(-०.२८) 1D
US$ ११.३९
arrow_downward
-०.२८% (-०.०३२)bedtimeAfter hours
Closed: अक्टोबर ५, १६:००:०१ GMT-४ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HELP...
Open
US$ ११.५०
High
US$ ११.७४
Low
US$ ११.२३
Avg. vol.
१७.१५ लाख
Volume
०.००
52-wk high
US$ १५.१५
52-wk low
US$ ३.७६
Beta
०.५३
Shares outstanding
७.३१ करोड
No. of employees
१००
Open
US$ ११.५०
High
US$ ११.७४
Low
US$ ११.२३
Avg. vol.
१७.१५ लाख
Volume
०.००
52-wk high
US$ १५.१५
52-wk low
US$ ३.७६
Beta
०.५३
Shares outstanding
७.३१ करोड
No. of employees
१००
News stories
From web sources and news partners
TipRanks
·
१६ घण्टा पहिले
Helus Pharma Files October Form 6-K and Corporate Amendment with U.S. SEC
Profile
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, deupsilocin, deudimethyltryptamine, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, deupsilocin is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
About Cybin Inc